APA (7th ed.) Citation

Cortellini, A., Garbo, E., La Cava, G., Citarella, F., Santo, V., Brunetti, L., . . . Signorelli, D. (2025). Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer (01695002), 209, N.PAG. https://doi.org/10.1016/j.lungcan.2025.108799

Chicago Style (17th ed.) Citation

Cortellini, Alessio, et al. "Long-term Outcomes from Pembrolizumab Monotherapy in Patients with Advanced NSCLC, PD-L1 Expression ≥ 50 %, and Poor Performance Status: Transformer-based AI to Characterize Prognostic Complexity." Lung Cancer (01695002) 209 (2025): N.PAG. https://doi.org/10.1016/j.lungcan.2025.108799.

MLA (9th ed.) Citation

Cortellini, Alessio, et al. "Long-term Outcomes from Pembrolizumab Monotherapy in Patients with Advanced NSCLC, PD-L1 Expression ≥ 50 %, and Poor Performance Status: Transformer-based AI to Characterize Prognostic Complexity." Lung Cancer (01695002), vol. 209, 2025, p. N.PAG, https://doi.org/10.1016/j.lungcan.2025.108799.